Kristen Kluska's Stock Ratings

Cantor Fitzgerald Analyst

Kristen Kluska is an analyst at Cantor Fitzgerald. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 05/16/2024

Overall Average Return

40.1%

Smart Score

75.9%

Overall Average Return Percentile

92nd

Number of Ratings

109
Buy NowGet Alert
05/16/2024ABEOBuy Now
Abeona Therapeutics
$4.58358.52%$28 → $21MaintainsOverweightGet Alert
05/16/2024MREOBuy Now
Mereo BioPharma Group
$3.17120.82% → $7ReiteratesOverweight → OverweightGet Alert
05/15/2024IRONBuy Now
Disc Medicine
$31.92166.29% → $85ReiteratesOverweight → OverweightGet Alert
05/15/2024TSHABuy Now
Taysha Gene Therapies
$3.09126.4% → $7ReiteratesOverweight → OverweightGet Alert
05/14/2024CAPRBuy Now
Capricor Therapeutics
$5.8037.93% → $8ReiteratesOverweight → OverweightGet Alert
05/10/2024ADMABuy Now
ADMA Biologics
$9.109.84%$8 → $10MaintainsOverweightGet Alert
05/03/2024RAREBuy Now
Ultragenyx Pharmaceutical
$44.25141.78% → $107ReiteratesOverweight → OverweightGet Alert
05/02/2024SRPTBuy Now
Sarepta Therapeutics
$132.74-3.57% → $128ReiteratesNeutral → NeutralGet Alert
04/30/2024TSHABuy Now
Taysha Gene Therapies
$3.09126.4% → $7ReiteratesOverweight → OverweightGet Alert
04/30/2024ATNMBuy Now
Actinium Pharma
$10.09108.13% → $21ReiteratesOverweight → OverweightGet Alert
04/23/2024ABEOBuy Now
Abeona Therapeutics
$4.58686.03% → $36ReiteratesOverweight → OverweightGet Alert
04/19/2024TSHABuy Now
Taysha Gene Therapies
$3.09126.4% → $7ReiteratesOverweight → OverweightGet Alert
04/18/2024TSHABuy Now
Taysha Gene Therapies
$3.09126.4% → $7ReiteratesOverweight → OverweightGet Alert
04/12/2024PTCTBuy Now
PTC Therapeutics
$34.0332.24% → $45ReiteratesOverweight → OverweightGet Alert
04/05/2024ETNBBuy Now
89bio
$9.07219.56% → $29ReiteratesOverweight → OverweightGet Alert
04/05/2024RAREBuy Now
Ultragenyx Pharmaceutical
$44.25141.78% → $107ReiteratesOverweight → OverweightGet Alert
04/01/2024HUMABuy Now
Humacyte
$6.448.7% → $7ReiteratesOverweight → OverweightGet Alert
04/01/2024ATNMBuy Now
Actinium Pharma
$10.09108.13% → $21ReiteratesOverweight → OverweightGet Alert
03/28/2024MREOBuy Now
Mereo BioPharma Group
$3.17120.82% → $7ReiteratesOverweight → OverweightGet Alert
03/22/2024MREOBuy Now
Mereo BioPharma Group
$3.17120.82% → $7ReiteratesOverweight → OverweightGet Alert
03/22/2024CLDXBuy Now
Celldex Therapeutics
$39.9467.75% → $67ReiteratesOverweight → OverweightGet Alert
03/20/2024TSHABuy Now
Taysha Gene Therapies
$3.09126.4% → $7ReiteratesOverweight → OverweightGet Alert
03/06/2024RIGLBuy Now
Rigel Pharmaceuticals
$0.99203.03%$2 → $3MaintainsNeutralGet Alert
03/04/2024ETNBBuy Now
89bio
$9.07219.56% → $29ReiteratesOverweight → OverweightGet Alert
03/01/2024PTCTBuy Now
PTC Therapeutics
$34.0332.24% → $45ReiteratesOverweight → OverweightGet Alert
02/29/2024ADMABuy Now
ADMA Biologics
$9.10-12.12%$6.5 → $8MaintainsOverweightGet Alert
02/29/2024FOLDBuy Now
Amicus Therapeutics
$9.46132.56% → $22ReiteratesOverweight → OverweightGet Alert
02/29/2024SRPTBuy Now
Sarepta Therapeutics
$132.74-3.57% → $128ReiteratesNeutral → NeutralGet Alert
02/27/2024RAREBuy Now
Ultragenyx Pharmaceutical
$44.25141.78% → $107MaintainsOverweightGet Alert
02/15/2024SRPTBuy Now
Sarepta Therapeutics
$132.74-3.57% → $128ReiteratesNeutral → NeutralGet Alert